Bayer Stock at a Crossroads: Landmark Ruling Looms as Kidney Drug Shows Promise

Bayer's Finerenon shows CKD benefit in Phase III, opening new market, but glyphosate lawsuits and Supreme Court ruling threaten financial stability, keeping stock near €35.90.

Bayer finds itself caught between two very different catalysts this summer. On one side, a promising Phase III study for its kidney drug Finerenon has just been published in the New England Journal of Medicine, bolstering hopes for a broader FDA approval. On the other, a US Supreme Court decision threatens to shape the company’s legal future for years. The stock, hovering near 35.90 euros, reflects this tug-of-war — operational strength and pipeline progress weighed down by a toxic legal overhang.

Finerenon delivers a strong data set

The FIND-CKD trial met its primary endpoint, showing that Kerendia (Finerenon) significantly slows kidney function decline in patients with non-diabetic chronic kidney disease. The drug also cut the risk of major cardiovascular complications compared with placebo. Bayer presented the data at a medical conference in Glasgow in early June, while the New England Journal of Medicine published the results simultaneously. With an estimated 850 million people worldwide suffering from chronic kidney disease — many without diabetes — the expanded indication could unlock a large new patient pool.

Bayer now plans to submit the data to the FDA for a label expansion. Separately, the agency granted a fast-track designation in May for Finerenon in type-1 diabetes, which would make it the first drug in its class approved for that group. Both regulatory pathways are critical for a pharma pipeline that badly needs a new blockbuster.

Legal bills drain the cash pile

Yet no amount of clinical success can mask the balance-sheet damage from US litigation. In the first quarter, Bayer burned through roughly 2.3 billion euros in free cash flow, largely due to payments for glyphosate and PCB lawsuits. Net debt climbed above 32.5 billion euros by the end of March. For the full year 2026, management expects a negative free cash flow of around 5 billion euros, to be financed through debt and bonds. The board explicitly rules out a capital increase.

The most immediate legal milestone is a ruling in the “Durnell” case, where the Supreme Court will decide whether a company can be held liable under state law even when the federal EPA has deemed the product safe. A favourable verdict could eliminate a large portion of the roughly 65,000 outstanding cases. An unfavourable one would keep the litigation machine rolling. That decision is expected this summer, and the stock moves with every rumour.

Meanwhile, the deadline for objections to the latest class-action settlement for glyphosate cases passed on 4 June, with a final court hearing set for July. A positive outcome there would at least provide some near-term closure.

Operations hold up, but margins feel the squeeze

Despite the legal turmoil, the underlying business delivered a decent first quarter. Group revenues, adjusted for currency effects, rose just over 4% to 13.4 billion euros. Operating profit climbed 9% to nearly 4.5 billion euros, helped by solid growth in the agriculture division. The consumer health unit, however, saw a different story: sales reached 1.49 billion euros, but higher marketing spend and currency headwinds pushed adjusted EBITDA down 1.5% to 337 million euros.

That mixed performance leaves the stock wrestling with the 200-day moving average of 35.95 euros. At last check, the shares traded at 35.87 euros — a hair’s breadth below that technical level. Since the start of the year, the stock has dropped roughly 5.5%, a slide that reflects deep investor scepticism rather than any fundamental collapse in the core business.

New faces, same structural pressure

Chief executive Bill Anderson has been shaking up the management team. Dr Judith Hartmann took over as chief financial officer at the beginning of June, succeeding Wolfgang Nickl as planned. The consumer health division also got a new marketing chief and a new US president, part of a broader push to revive growth in that unit.

But personnel changes alone cannot fix a balance sheet saddled by litigation costs and a market capitalisation of around 35 billion euros that implicitly prices in unresolved legal risk. The new CFO inherits a business where the free-cash-flow deficit is effectively a lawsuit ledger.

For now, Bayer’s share price remains a bet on the courtroom, not the laboratory. The clinical win for Finerenon is real and could eventually reshape the investment case. But until the Supreme Court and the settlement hearings provide some relief, the stock will likely remain stuck in no-man’s land — a fundamentally sound operator trapped in a legal quagmire.